Arnold, Susanne M.
Chansky, Kari
Leggas, Markos
Thompson, Michael A.
Villano, John L.
Hamm, John
Sanborn, Rachel E.
Weiss, Glen J.
Chatta, Gurkamal
Baggstrom, Maria Q.
Funding for this research was provided by:
Onyx pharmaceuticals, subsidiary of Amgen
Article History
Received: 12 January 2017
Accepted: 2 February 2017
First Online: 16 February 2017
Compliance with ethical standards
: All subjects underwent an IRB-approved informed consent process prior to any research procedures, as required by the IRB of record for each institution.
: No animal research was undertaken.
: The authors disclose research funding received from Onyx pharmaceuticals, subsidiary of Amgen.Susanne M. Arnold, MD, discloses a potential conflict of interst with research funding by Onyx pharmaceuticals, subsidiary of Amgen. There are no potential conflicts for interests for authors Kari Chansky, PhD; Markos Leggas, PhD; Michael A. Thompson, MD, PhD; John L. Villano, MD, PhD; John Hamm, MD; Rachel E. Sanborn, MD; Glen J. Weiss, MD, MBA; Gurkamal Chatta, MD; or Maria Q. Baggstrom, MD.